APLT Applied Therapeutics Inc.

Biotech Analyst Ratings

Latest News

1. 12 May 2022 Applied Therapeutics Reports First Quarter 2022 Financial Results

   NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for the first quarter ended March 31, 2022.
   

   "We made significant progress in the first quarter across all three of our Phase 3 programs," said Shoshana Shendelman, PhD, Founder and CEO of Applied Therapeutics. "We are pleased to have reached alignment with the FDA on Galactosemia, and are excited about the expected milestones in the year ahead."

   Recent Highlights

   • Provided Regulatory Update on Galactosemia Program. In January 2022, the Company announced…

   View Full Article
2. 05 May 2022 Applied Therapeutics to Present Data on AT-007 Treatment in SORD Deficiency at the 2022 Annual Meeting of the Peripheral Nerve Society

   • Sorbitol correlates with disease severity in patients with SORD Deficiency
   • AT-007 treatment substantially reduced sorbitol levels in a pilot study in SORD Deficiency
   • Sorbitol elevation results in mitochondrial dysfunction, neuronal loss, and climbing defects in a drosophila model of SORD Deficiency; AT-007 treatment in drosophila prevents all aspects of the SORD Deficiency phenotype by reducing sorbitol production

   NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced presentations at the 2022 Annual Meeting of the Peripheral Nerve…

   View Full Article
3. 04 April 2022 Applied Therapeutics to Present at the 43rd Annual Meeting of the Society for Inherited Metabolic Disorders

   NEW YORK, April 04, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced poster presentations at the 2022 43^rd Annual Meeting of the Society for Inherited Metabolic Disorders, April 10 - 13, 2022 in Orlando, Florida.
   

   "Baseline data from the ACTION-Galactosemia Kids study illustrates the high burden of disease associated with Galactosemia, including neurological complications, due to high galactitol levels," said Riccardo Perfetti, MD, PhD, Chief Medical Officer of Applied Therapeutics. "This data underscores the urgent need to bring a treatment…

   View Full Article
4. 16 March 2022 Applied Therapeutics to Present at the 2022 Annual Clinical Genetics Meeting of the American College of Molecular Genetics and Genomics

   NEW YORK, March 16, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced their abstract #OP005 was accepted as an oral platform presentation at the 2022 Annual Clinical Genetics Meeting of the American College of Molecular Genetics and Genomics, March 22 – 26, 2022 in Nashville, Tennessee.
   

   "We are pleased to share this important data with the medical community," said Riccardo Perfetti, MD, PhD, Chief Medical Officer of Applied Therapeutics. "We demonstrated that galactitol levels correlated with the severity of the CNS deficits in pediatric patients…

   View Full Article
5. 10 March 2022 Applied Therapeutics Reports Fourth Quarter and Year-end 2021 Financial Results

   NEW YORK, March 10, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for the fourth quarter and full year ended December 31, 2021.
   

   "We remain committed to bringing new treatments to patients in areas of high unmet need," said Shoshana Shendelman, PhD, Founder and CEO of Applied Therapeutics. "With three ongoing Phase 3 studies across Galactosemia, Sorbitol Dehydrogenase (SORD) Deficiency and Diabetic Cardiomyopathy, we are advancing treatments forward, and expect multiple catalysts and opportunities for value creation in…

   View Full Article